ArticleMolecular cancer therapeutics2023

Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.

Funda Meric-Bernstam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.